6-K
File 001-15170
GSK'S NUCALA APPROVED IN CHINA FOR USE IN CRSWNP
- Filing date
- 03 Jan 2025
- Reporting date
- 03 Jan 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
GSK plc reports
- Company location
- London
GSK plc has filed 6,798 SEC EDGAR filings since 12 Jan 2001
SEC filing history
Showing 551-575 of 1,000 matching filings.
Per page
25
Current page
23
6-K
File 001-15170
TOTAL VOTING RIGHTS
- Filing date
- 02 Jan 2025
- Reporting date
- 02 Jan 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 23 Dec 2024
- Reporting date
- 23 Dec 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
BLOCK LISTING APPLICATION
- Filing date
- 20 Dec 2024
- Reporting date
- 20 Dec 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
HEADLINE RESULTS FROM PHASE III FIRST TRIAL
- Filing date
- 20 Dec 2024
- Reporting date
- 20 Dec 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
JEMPERLI RECEIVES US FDA BREAKTHROUGH DESIGNATION
- Filing date
- 16 Dec 2024
- Reporting date
- 16 Dec 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
EMA GRANTS PRIME DESIGNATION FOR GSK 227
- Filing date
- 16 Dec 2024
- Reporting date
- 16 Dec 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
JEMPERLI RECEIVES POSITIVE CHMP OPINION
- Filing date
- 16 Dec 2024
- Reporting date
- 16 Dec 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 12 Dec 2024
- Reporting date
- 12 Dec 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
OVERALL SURVIVAL DATA PRESENTED FOR BLENREP
- Filing date
- 09 Dec 2024
- Reporting date
- 09 Dec 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
BLENREP COMBINATION CHINA FILING ACCEPTANCE
- Filing date
- 09 Dec 2024
- Reporting date
- 09 Dec 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
NUCALA COPD SUBMISSION ACCEPTED BY US FDA
- Filing date
- 09 Dec 2024
- Reporting date
- 09 Dec 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
ZHIFEI CHINA COLLABORATION REVISED AND EXTENDED
- Filing date
- 05 Dec 2024
- Reporting date
- 05 Dec 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 02 Dec 2024
- Reporting date
- 02 Dec 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TOTAL VOTING RIGHTS
- Filing date
- 02 Dec 2024
- Reporting date
- 02 Dec 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK LIQUID MENINGITIS VACCINE AUTHORISED IN EU
- Filing date
- 27 Nov 2024
- Reporting date
- 27 Nov 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
BLENREP COMBINATIONS ACCEPTED FOR US FDA REVIEW
- Filing date
- 25 Nov 2024
- Reporting date
- 25 Nov 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
JAPAN APPROVES FIRST RSV VACCINE FOR ADULTS 50-59
- Filing date
- 22 Nov 2024
- Reporting date
- 22 Nov 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 19 Nov 2024
- Reporting date
- 19 Nov 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GLISTEN TRIAL OF LINERIXIBAT MEETS ENDPOINT
- Filing date
- 19 Nov 2024
- Reporting date
- 19 Nov 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SC 13D/A
AMENDMENT TO THE SCHEDULE 13D
- Filing date
- 15 Nov 2024
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK ANNOUNCES OVERALL SURVIVAL RESULTS FOR BLENREP
- Filing date
- 14 Nov 2024
- Reporting date
- 14 Nov 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
BLOCK LISTING INTERIM REVIEW
- Filing date
- 13 Nov 2024
- Reporting date
- 13 Nov 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SC 13G/A
File 005-84251
AMENDMENT TO FORM SC 13G
- Filing date
- 12 Nov 2024
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 12 Nov 2024
- Reporting date
- 12 Nov 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing